Validation Study of Linear Quantification of CD3+ Cells in Localized Colorectal Carcinomas
NCT02364024 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 856
Last updated 2018-07-06
Summary
The purpose of this study is to confirm that linear quantification of CD3+ cells is a prognostic biomarker in localized colorectal carcinomas.
Conditions
Sponsors & Collaborators
-
Federation Francophone de Cancerologie Digestive
lead OTHER
Principal Investigators
-
Emile Jean-François, Pr · Fédération Fancophone de Cancérologie Digestive
Eligibility
- Min Age
- 18 Years
- Max Age
- 74 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2005-11-30
- Primary Completion
- 2009-05-31
- Completion
- 2017-04-30
More Related Trials
-
Prognostic Value of the Immunoscore® Colon Test for Disease Free Survival Stratification in Stage III Patients Under Oxaliplatin Treatment
NCT03422601 ·Status: UNKNOWN
-
iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab
NCT03350126 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer
NCT00559676 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer
NCT04468607 ·Status: COMPLETED ·Phase: PHASE1
-
Multiparametric Characterization of Colorectal Cancers (METRAD)
NCT07000474 ·Status: ACTIVE_NOT_RECRUITING
-
Analysis of Circulating Tumor DNA to Monitor Metastatic Colorectal Cancer Treatment
NCT01983098 ·Status: UNKNOWN
-
mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC
NCT06791512 ·Status: RECRUITING ·Phase: PHASE3
-
Clinical Application of PD-1 Inhibitor in Colorectal Cancer for Improving Survival
NCT06900686 ·Status: COMPLETED
-
M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability
NCT03436563 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer
NCT07123441 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
PET/CT Scan as a Tool to Rationalize the Treatment of Patients With Advanced ColoRectal Cancer Undergoing First-line Medical Treatment
NCT02618850 ·Status: UNKNOWN ·Phase: NA
-
ZN-c3 in Adult Participants With Metastatic Colorectal Cancer
NCT05743036 ·Status: TERMINATED ·Phase: PHASE1
-
Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer
NCT03592641 ·Status: TERMINATED ·Phase: PHASE2
-
The Theranostic Value of STARD3 in Colorectal Cancer: The STAR Study
NCT06136949 ·Status: RECRUITING
-
Biomarkers in Predicting Response to Cetuximab in Patients With Advanced Colorectal Cancer
NCT01243372 ·Status: COMPLETED
-
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
NCT06663319 ·Status: RECRUITING ·Phase: PHASE1
-
Study and Modulation of Immune Responses in Primary and Metastatic Colon Cancers
NCT06435689 ·Status: NOT_YET_RECRUITING
-
Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer
NCT06225622 ·Status: RECRUITING ·Phase: PHASE1
-
QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters.
NCT03828227 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study Evaluating the Influence of LV5FU2 Bevacizumab Plus Anakinra Association on Metastatic Colorectal Cancer
NCT02090101 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Target-Guided Chemotherapy in Metastatic Colorectal Patients
NCT01453257 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC
NCT06643793 ·Status: RECRUITING ·Phase: PHASE2
-
Diagnostic Procedure for Identifying Patients With Metastatic Colorectal Cancer
NCT00003186 ·Status: COMPLETED ·Phase: NA
-
A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer
NCT05639413 ·Status: RECRUITING ·Phase: NA
-
A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC
NCT03303495 ·Status: UNKNOWN ·Phase: PHASE3